Robert Gentleman has shared details of what he wants to achieve as 23andMe's VP of computational biology. And the ex-Genentech bioinformatics chief is looking to turn 23andMe's inexperience in drug discovery into a strength, notably by relying more on computational methods to generate data in early-stage tests.
Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.
Apple has designs on the DNA sequencing sector. The tech giant is reportedly working with researchers to make 23andMe-style DNA sequencing spit kits part of ResearchKit, the platform that turned every iPhone user into a potential study participant.
Controversial genetic testing company 23andMe is finding new ways to stay relevant after the FDA yanked its popular--and once lucrative--direct-to-consumer diagnostic from the market in 2013.
The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.
Researchers at the University of Michigan are trying to speed toward their goal of enrolling 20,000 people in a study by piggybacking onto Facebook's vast social network. And the genotypic and phenotypic data gathering project is off to a brisk start, with more than 2,000 people signing up in the days after its public launch.
23andMe, the Silicon Valley maker of personalized gene tests, has picked off another Genentech luminary to help it evolve into a biotech company, recruiting the famed drugmaker's head of bioinformatics.
23andMe is making its first foray into retail, teaming up with U.K. health and beauty company Superdrug to sell its genetic tests in the country.
23andMe has charted a different course since running afoul of the FDA for its genetic testing products in 2013, inking deals with biopharma heavyweights to provide genomic data for drug development. Now the Google-backed company is riding the tailwinds of change, unveiling a new therapeutics group with a biotech veteran at its helm.
23andMe has brought in the former EVP of research and early development from Genentech, Richard Scheller, as CSO and head of a newly created therapeutics group. The move seems likely to be a precursor to a major cash infusion.